合作共赢|医药卫生交流合作委员会与天津和创生物技术有限公司达成战略合作
4月19日,医药卫生交流合作委员会与天津和创生物技术有限公司正式签署战略合作框架协议。医药卫生交流合作委员会会长杨光林,天津药物研究院副院长、和创生物总经理闫凤英出席签约仪式并致辞。
杨光林会长致辞
杨光林会长在致辞中表示,医药卫生交流合作委员会致力于搭建国际化医药卫生产业交流平台,促进推动各国医药事业的交流往来,推动科研机构、医学院校、医药企业开展广泛深入合作,协同科研成果的高效转化,助力实现学、研、产、销、投一体化的全面合作与通路保障。天津和创生物技术有限公司作为天津药物研究院布局的生物技术板块平台,在细胞产品及相关技术研究领域,具有深厚的科研基础和前瞻的发展势能。此次签约致力于促进多方协同共赢,让中国先进的科研成果和医疗技术得到及时的转化和广泛的推广,助力科研成果价值转化,助力企业国际市场开拓。
闫凤英副院长致辞
闫凤英副院长在致辞中表示,此次和创与委员会的合作是强强联合。和创生物是由天津药物研究院与中国医学科学院血液学研究所合作创建,是天津市细胞技术创新中心的载体平台。希望未来双方能够充分发挥各自优势,尽快形成务实合作,实现互惠共赢。希望以和创生物开启合作起点,下一步深入拓展医药卫生交流合作委员会与天津药物研究院在业务合作、资源共享、联合开发等方面进行全方位的战略合作。
双方签署战略合作协议,同意在医药、功能性食品、保健品转化和注册备案登记以及清真国际认证;开拓干细胞抗衰老、医美等科研产品在境内外的注册和使用等方面展开合作。
签约仪式后,双方展开交流座谈,探讨了未来医学的发展方向、生物样本库建设等生物医药领域的前沿话题。
杨光林会长在闫凤英副院长的带领下,参观了和创生物细胞产品GMP车间,了解了和创生物的业务范围和前沿技术。
医药卫生交流合作委员会愿同社会各界关心医药卫生事业国际化发展,医学人才教育培养,医学成果转化与产业孵化的朋友们一道,积极参与融入到国内外双循环,多平台的新发展格局中,为扩大国际合作,促进我国生物医药产业走向世界树立形象,搭建桥梁,为我国卫生健康事业发展和构建人类卫生健康共同体不断做出努力和贡献。
Abstract
On April 19, the Health and Medical Exchange Cooperation Committee and Tianjin Hechuang Biotechnology Co., Ltd. formally signed the strategic cooperation framework agreement. Yang Guanglin, Chairman of the Health and Medical Exchange Cooperation Committee, and Yan Fengying,Vice President of Tianjin Institute of Pharmaceutical Research, General Manager of Hechuang Biotechnology Co., Ltd. , attended the signing ceremony and delivered speeches. The two parties agreed to cooperate in the transformation and registration of medicines, functional foods, and health products, as well as the registration of Halal international certification; the registration and use of scientific research products such as stem cell anti-aging and medical beauty in China and abroad.
The Health and Medical Exchange Cooperation Committee is willing to work with friends from all sectors of society who are concerned about the international development of the medical and health industry, the education and training of medical talents, the transformation of medical achievements and industrial incubation, to actively participate in the new development pattern of domestic and international dual circulation, and multi-platforms. In order to establish an image and build a bridge for expanding international cooperation and promoting China’s biomedical industry to the world, and make continuous efforts and contributions to the development of China’s health care and the construction of a human health community of shared future.